Endowed Chair awarded
We are delighted to share that Professor Amynah Pradhan has been awarded a prestigious Endowed Chair at Washington University, where she now serves as the Russell D. and Mary B. Shelden Professor of Anesthesiology.
Amynah is internationally recognised for her contributions to pharmacology. Among her many achievements, she identified the delta opioid receptor as a novel therapeutic target for various pain conditions — discoveries that have catalysed clinical development programmes now advancing through trials.
PharmNovo has been privileged to collaborate with Amynah over the past several years on the development of PN6047 as a potential treatment for neuropathic pain, headache, and opioid withdrawal syndrome, supported by a grant from the U.S. National Institute on Drug Abuse (NIDA). The results of this work are currently being prepared for publication.
We would also like to acknowledge Professor Emily Jutkiewicz, another key partner in this research, who was awarded an endowed Chair at the University of Michigan shortly before her tragic passing in 2024. Emily’s scientific insight and commitment were deeply valued, and she is greatly missed.
Everyone at PharmNovo feels fortunate to have worked closely with these two exceptional colleagues, and we again offer our sincere congratulations to Amynah.
Endowed Chair awarded
We are delighted to share that Professor Amynah Pradhan has been awarded a prestigious Endowed Chair at Washington University, where she now serves as the Russell D. and Mary B. Shelden Professor of Anesthesiology.
Amynah is internationally recognised for her contributions to pharmacology. Among her many achievements, she identified the delta opioid receptor as a novel therapeutic target for various pain conditions — discoveries that have catalysed clinical development programmes now advancing through trials.
PharmNovo has been privileged to collaborate with Amynah over the past several years on the development of PN6047 as a potential treatment for neuropathic pain, headache, and opioid withdrawal syndrome, supported by a grant from the U.S. National Institute on Drug Abuse (NIDA). The results of this work are currently being prepared for publication.
We would also like to acknowledge Professor Emily Jutkiewicz, another key partner in this research, who was awarded an endowed Chair at the University of Michigan shortly before her tragic passing in 2024. Emily’s scientific insight and commitment were deeply valued, and she is greatly missed.
Everyone at PharmNovo feels fortunate to have worked closely with these two exceptional colleagues, and we again offer our sincere congratulations to Amynah.
Latest news
View all
Watch PharmNovo at LSX in Lisbon
Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.
Read more
Capsules ready for Phase IIa Study
PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.
Read more
Welcome on Board
As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.
Read more
CTA approval for PN6047
PharmNovo AB is pleased to announce that the clinical trial application (CTA) for a Phase IIa proof of concept (PoC) study investigating the safety and efficacy of lead candidate PN6047 in patients with neuropathic pain has been approved in Spain. The full title of the study is: “Randomized Double-Blind Placebo-Controlled Cross-Over Trial of the Safety, Tolerability, and Efficacy of PN6047 HCl in Peripheral Neuropathic Pain Characterized by Mechanical Allodynia.”
Read more